Scinai Immunotherapeutics (SCNI) Total Liabilities (2015 - 2026)

Scinai Immunotherapeutics has disclosed Total Liabilities across 12 years of filings, most recently posting $5.4 million for Q2 2026.

• In Q2 2026, Total Liabilities rose 36.69% year-over-year to $5.4 million; the TTM figure through Jun 2026 stood at $5.4 million (up 36.69% YoY), while the FY2025 annual figure was $3.5 million, up 1.5% from the prior year.
• Total Liabilities came in at $5.4 million for Q2 2026 at Scinai Immunotherapeutics, down from $5.8 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $28.8 million in Q4 2022 to a low of $862000.0 in Q1 2022.
• Average Total Liabilities over 5 years is $14.8 million, with a median of $19.8 million recorded in 2022.
• Year-over-year, Total Liabilities soared 3160.09% in 2023 and slumped 89.39% in 2024.
• Over 5 years, Total Liabilities stood at $28.8 million in 2022, then fell by 23.54% to $22.0 million in 2023, then sank by 84.25% to $3.5 million in 2024, then rose by 1.5% to $3.5 million in 2025, then soared by 54.5% to $5.4 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $5.4 million in Q2 2026, $5.8 million in Q1 2026, and $3.5 million in Q4 2025.